Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon PharmaLTS:0RKX 19 EV-to-EBIT is 5.39 as of Aug. 13, 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 681 Drug Manufacturers companies, Celon Pharma ranks better than 88.69% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Celon Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was zł1,263.7 Mil.
Celon Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł159.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma EV-to-EBIT Related Terms
Celon Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Celon Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Celon Pharma's EV-to-EBIT falls into.
Celon Pharma's current Enterprise Value is zł859.3 Mil.
Celon Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł159.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (LTS:0RKX) has a EV-to-EBIT of 5.39 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #77 out of 681 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Celon Pharma's EV-to-EBIT too high?
Celon Pharma's current EV-to-EBIT is 5.39. The Drug Manufacturers industry median EV-to-EBIT is 15.76. Celon Pharma's value of 5.39 is 65.8% below this industry median. Based on the distribution chart, Celon Pharma ranks #77 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #77 out of 681 companies for EV-to-EBIT. This places Celon Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.76. Celon Pharma's value of 5.39 is 65.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.76, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current EV-to-EBIT of 5.39 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current EV-to-EBIT is 5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current EV-to-EBIT of 5.39. The current EV-to-EBIT is 5.39 and 65.8% below the Drug Manufacturers industry median of 15.76. Celon Pharma's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current EV-to-EBIT is 5.39 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
19GF Score
Get the complete analysis for LTS:0RKX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
